vTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Rating of “Moderate Buy” by Analysts

vTv Therapeutics Inc. (NASDAQ:VTVT) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $55.25.

A number of research analysts recently issued reports on VTVT shares. TD Cowen assumed coverage on vTv Therapeutics in a report on Monday, January 5th. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Wall Street Zen upgraded shares of vTv Therapeutics to a “sell” rating in a report on Saturday, December 27th. Roth Mkm initiated coverage on vTv Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 target price for the company. Finally, BTIG Research reissued a “buy” rating and set a $49.00 price target (up from $40.00) on shares of vTv Therapeutics in a report on Tuesday.

vTv Therapeutics Trading Up 0.3%

VTVT opened at $34.15 on Friday. vTv Therapeutics has a 12-month low of $14.00 and a 12-month high of $44.00. The stock has a market capitalization of $134.55 million, a P/E ratio of -10.29 and a beta of 0.48. The stock has a 50-day moving average price of $34.27 and a 200-day moving average price of $25.07.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.11).

Hedge Funds Weigh In On vTv Therapeutics

A hedge fund recently raised its stake in vTv Therapeutics stock. Baker BROS. Advisors LP lifted its stake in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned about 3.77% of vTv Therapeutics worth $3,463,000 as of its most recent filing with the Securities & Exchange Commission. 17.51% of the stock is owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.